药明合联 2026 年上半年业绩:业务稳步推进,利润率与盈利规模持续提升,夯实全球ADC/XDC CRDMO 领先地位

美通社
Yesterday

集团营业收入增至 37.01 亿元人民币,按实际汇率(AER1)计算同比增长 37.0%,按固定汇率(CER2)计算同比增长41.5%。 集团毛利同比增长 40.6%,至 13.71亿元人民币;毛利率为 37.0%,较 2025 年上半年提升 0.9 个百分点。 经调整归属母公司净利润同比增长 37.4%,至 10.27 亿元人民币;经调整归属母公司净利润率保持稳健为 27.8%,较 2025 年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10